ALX Oncology Holdings Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for ALXO, updated each market day.
ALXO AI Sentiment
AI predicts ALX Oncology Holdings Inc. Common Stock stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About ALX Oncology Holdings Inc. Common Stock
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Sector
Exchange
Market Cap
$223,734,072
Cap Tier
Employees
43
Headquarters
SOUTH SAN FRANCISCO, CA
Listed Since
July 17, 2020
Website
ALXO Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ALXO Volatility
ALX Oncology Holdings Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
